StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $5.82 | $5.70 | -2.06% | 0.1M |
| 05-14 | $5.70 | $5.76 | +1.05% | 0.2M |
| 05-15 | $5.57 | $5.25 | -5.75% | 0.2M |
| 05-18 | $5.22 | $5.84 | +11.88% | 0.3M |
| 05-19 | $5.97 | $5.83 | -2.35% | 0.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Each factor shows PSTV's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Q1 2019 2019-03-31 | Annual 2018 2018-12-31 | Q3 2018 2018-09-30 | Q1 2018 2018-03-31 |
|---|---|---|---|---|---|
Revenue | $1.26M | $703.00K | $3.67M | $2.25M | $731.00K |
Operating Income | Not available | $-2.17M | $-8.76M | $-6.85M | $-4.35M |
Net Income | Not available | $-3.15M | $-12.63M | $-10.40M | $-4.41M |
EPS (Diluted) | $-0.85 | Not available | Not available | Not available | Not available |
Total Assets | Not available | $24.62M | $23.99M | $25.53M | $26.64M |
Total Liabilities | Not available | $20.76M | $18.77M | $19.39M | $18.16M |
Cash & Equivalents | Not available | $3.87M | $5.26M | $6.81M | $5.90M |
Free Cash Flow OCF − CapEx | Not available | $-3.28M | $-12.11M | $-9.62M | $-4.17M |
Shares Outstanding | Not available | 14.83M | 296.61K | 11.69M | 61.61M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.